High-sensitivity C-reactive protein (CRP) decreased significantly in the semaglutide group, with estimated treatment ratios ...

A retrospective real-world study strengthens evidence that early, sustained treatment with the antiamyloid lecanemab can slow ...

A deep analysis of semaglutide’s phase 3 AD trials shows no cognitive or functional benefit despite biomarker gains, yet ...

Down syndrome is caused by an extra copy of chromosome 21. Because of genes present on this chromosome that are known to ...

Days after Johnson & Johnson’s posdinemab failed to slow clinical decline in patients with Alzheimer’s disease, Eisai Chief Clinical Officer Lynn Kramer expressed unwavering conviction in his ...

The outlook for dementia care is changing fast. UC experts explain what that means for patients and families, and what it ...

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow ...

GLP-1 drugs, which include Ozempic and Wegovy, have become one of the most closely watched experimental approaches for ...

There have been some interesting failures recently in Alzheimer’s trials. Two are notable because they’re aimed outside the ...

Novo, which in September said it secured Indian regulatory approval to import and sell Ozempic, on Thursday said it hoped to ...

Novo Nordisk A/S left open the door for additional work on its pill version of Ozempic for Alzheimer’s disease after a pair ...

Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people ...